Anadys Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing ANA598, a small-molecule, non- nucleoside inhibitor of the NS5B polymerase for the treatment of HCV and ANA773, an oral TLR7 agonist prodrug for cancer.
Safe Harbor Statement
Statements in this press release that are not strictly historical in
nature constitute "forward-looking statements." Such statements include,
but are not limited to, references to the expected timing and planned
development activities for ANA598 and ANA773, including the timing for
initiating clinical trials, the belief that Anadys' investment in the
ANA598 and ANA773 programs will create value for the company, the
anticipated future clinical benefits of ANA598 and ANA773, Anadys' ability
to achieve meaningful clinical milestones with existing cash reserves and
the ability to modulate immunostimulatory responses to ANA773 by schedule
of administration. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors, which may cause Anadys'
actual results to be materially different from historical results or from
any results expressed or implied by such forward- looking statements. For
example, the results of preclinical studies may not be predictive of future
results, and Anadys cannot provide any assurances that any of its product
candidates will not have unforeseen safety issues, will have favorable
results in future clinical trials or will receive regulatory approval. In
addition, Anadys' results may be aff
|SOURCE Anadys Pharmaceuticals, Inc.|
Copyright©2007 PR Newswire.
All rights reserved